Source: Health Canada shortage reports · Updated Nov 5, 2026
Some Deferoxamine products are in shortage in Canada (1 of 3 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Nov 23, 2026.
An iron chelator used to remove excess iron from the body.
Products affected
1 / 3
In shortage since
Nov 5, 2026
Est. full return
Nov 23, 2026
Reports on file
19
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
DEFEROXAMINE MESYLATE FOR INJECTION
2G · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02247022 · since Nov 5, 2026, est. end Nov 23, 2026 · Disruption of the manufacture of the drug.
Resolved
DEFEROXAMINE MESYLATE FOR INJECTION
500MG · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02241600 · ended Mar 24, 2025 · Disruption of the manufacture of the drug.
Resolved
DEFEROXAMINE MESYLATE FOR INJECTION
2G · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02247022 · ended Mar 11, 2025 · Disruption of the manufacture of the drug.
Resolved
DESFERAL 500MG
500MG · POWDER FOR SOLUTION · NOVARTIS PHARMACEUTICALS CANADA INC
DIN 01981242 · ended Jan 6, 2025 · Demand increase for the drug.
Resolved
DEFEROXAMINE MESYLATE FOR INJECTION
2G · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02247022 · ended Oct 23, 2024 · Disruption of the manufacture of the drug.
Resolved
DEFEROXAMINE MESYLATE FOR INJECTION
500MG · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02241600 · ended Oct 22, 2024 · Disruption of the manufacture of the drug.
Resolved
DESFERAL 500MG
500MG · POWDER FOR SOLUTION · NOVARTIS PHARMACEUTICALS CANADA INC
DIN 01981242 · ended Sep 5, 2024 · Demand increase for the drug.
Resolved
DESFERAL 500MG
500MG · POWDER FOR SOLUTION · NOVARTIS PHARMACEUTICALS CANADA INC
DIN 01981242 · ended Jun 17, 2024 · Demand increase for the drug.
Resolved
DEFEROXAMINE MESYLATE FOR INJECTION
500MG · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02241600 · ended Apr 24, 2024 · Disruption of the manufacture of the drug.
Resolved
DEFEROXAMINE MESYLATE FOR INJECTION
2G · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02247022 · ended Apr 17, 2024 · Disruption of the manufacture of the drug.
Resolved
DESFERAL 500MG
500MG · POWDER FOR SOLUTION · NOVARTIS PHARMACEUTICALS CANADA INC
DIN 01981242 · ended Sep 29, 2023 · Demand increase for the drug.
Resolved
DEFEROXAMINE MESYLATE FOR INJECTION
500MG · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02241600 · ended Aug 18, 2023 · Disruption of the manufacture of the drug.
Showing 12 of 19 reports. All reports are on file with Health Canada.
What's happening
Deferoxamine is currently affected by an active shortage report filed with Health Canada by PFIZER CANADA ULC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Deferoxamine is classified under “ALL OTHER THERAPEUTIC PRODUCTS” (ATC V03AC).
Recent changes
Nov 5, 2026
Status changed
Oct 29, 2026
New report filed
Common questions
What is Deferoxamine used for?
An iron chelator used to remove excess iron from the body.
When will Deferoxamine be back in stock in Canada?
The latest manufacturer estimate is Nov 23, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Deferoxamine in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.